Holen Sie sich die Stockscreener-App
2.78
4.91%
0.13
Handel nachbörslich:
2.82
0.04
+1.44%
Schlusskurs vom Vortag:
$2.65
Offen:
$2.75
24-Stunden-Volumen:
3.24M
Relative Volume:
1.43
Marktkapitalisierung:
$941.52M
Einnahmen:
$796.85M
Nettoeinkommen (Verlust:
$30.44M
KGV:
33.02
EPS:
0.0842
Netto-Cashflow:
$93.88M
1W Leistung:
+10.32%
1M Leistung:
+20.35%
6M Leistung:
-1.77%
1J Leistung:
-25.67%
1-Tages-Spanne:
$2.655
$2.88
1-Wochen-Bereich:
$2.46
$2.88
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.78 | 897.49M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
158.54 | 26.14B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
60.32 | 11.34B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.66 | 8.29B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
87.25 | 7.39B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
52.98 | 4.28B | 646.34M | -512.40M | 202.76M | -6.6871 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx Holdings Q3 2025 Earnings Preview - MSN
SA analyst upgrades/downgrades: NVDA, META, GDRX, JPM - Seeking Alpha
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
GoodRx: Evident Stabilization, But GLP-1 Dependence Is A Risk (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Holdings (GDRX) price target increased by 10.24% to 3.17 - MSN
The 5 Most Interesting Analyst Questions From GoodRx’s Q1 Earnings Call - Yahoo Finance
GoodRx (GDRX) CAO exercises RSUs and delivers shares to cover taxes - Stock Titan
GoodRx (NASDAQ: GDRX) executive exercises 44,779 RSUs, 19,726 shares for taxes - Stock Titan
GoodRx Holdings' (NASDAQ:GDRX) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
GDRX Maintained by Citigroup -- Price Target Raised to $4.00 - GuruFocus
GoodRx Holdings Is Maintained at Buy by Citigroup - Moomoo
Jim Cramer on GoodRx: “I’m Going to Grant You That Spec” - Insider Monkey
Some May Be Optimistic About GoodRx Holdings' (NASDAQ:GDRX) Earnings - simplywall.st
GDRX (NASDAQ: GDRX) Form 144 — 43,100-share proposed sale - Stock Titan
Why Jim Cramer Says 'Pull The Trigger' On Chevron - Benzinga
GoodRx (GDRX) awards 54,494 RSUs to Chief Accounting Officer Thomas Chan - Stock Titan
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises - Investing.com Nigeria
TradingKey - TradingKey
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and DaVita (DVA) - The Globe and Mail
GDRX Maintained by TD Cowen -- Price Target Raised to $4.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue - The Motley Fool
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2026 Earnings Call Transcript - Insider Monkey
GoodRx Earnings Call Highlights Pharma Direct Momentum - TipRanks
GoodRx (GDRX) Q1 2026 Earnings Call Transcript - The Globe and Mail
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com India
GoodRx Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Q1 2026 GoodRx Holdings Inc Earnings Call Transcript - GuruFocus
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS ; Offers Guidance - StreetInsider
Number of shareholders of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
GoodRx Holdings, Inc. (GDRX) Q1 earnings match estimates - MSN
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx Reports First Quarter 2026 Results - pharmiweb.com
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - Yahoo Finance
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Goodrx Holdings Inc-Aktie (GDRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
2.59%
3.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):